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respectively, with a median survival time, calculated from 
the date of metastasis and last follow-up or death, of 29.8 
months. 
 
Conclusion: These data suggest that stereotactic ablative 
radiotherapy (SABR) is a safe, non-invasive and effective 
option in the treatment of liver metastases. 
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Purpose or Objective: The aim of this study was to 
investigate the outcome and prognostic factors for patients 
with locally advanced gastric cancer (LAGC) treated with 
adyuvant radiochemotherapy, according Macdonald scheme. 
 
Material and Methods: Between May 2004 and October 2014, 
a total of 106 patients, 70 men and 36 women, with locally 
advanced gastric cancer were treated in the University 
Hospital 12 de Octubre, Spain. The mean age was 57 years 
.The mean follow-up was 96.48 months. The most common 
tumor location was antrum (29.25%). The majority of tumors 
were T3 (52.83%) or T4 (22.64 %) and 86.79 % had nodal 
metastases, with an average of 8.24 nodes involved. 
Predominant histological subtype was diffuse (43.4%) and 
poorly differentiated (grade 3, 50%). Complete resection (R0) 
was achieved 84.91%, whereas microscopic residual disease 
(R1) was found in 13.21%. Survival was calculated by Kaplan-
Meier and method and differences were assessed by the Log-
rank test. Multivariate analysis was used Cox proportional 
hazards regression model. 
 
Results: A total of 50 (47.16 %) patients relapsed; 16 (15.09%) 
locoregional, 13 (12.26%) peritoneal, 18 (16.98%) distant 
metastases and 3 (2.83%) unknown. The overall survival (OS), 
disease-free survival ( DFS), locoregional failure-free survival 
(LFS) rates to three years were 48.75%, 46.27% and 76.72% 
and to five years were 32.11%, 38.78%, 69.67% respectively. 
In univariate analysis, T stage (T1-T2), N negative stage and 
R0 resection were associated with better survival (p<0.05) for 
OS and only N negative stage for DFS and LFS. In the 
multivariate analysis indentified only R0 resection as an 
independent predictor of better survival (p<0.05) for OS and 
DFS. 
 
Conclusion: In this study, the prognostic factors associated 
with better survival in patients with LAGC treated with 
adyuvant radiochemotherapy were: T stage (T1-T2), N 
negative stage and R0 resection ( p< 0.05). Complete R0 
resection also can be considered as independent prognostic 
factor of better survival (p<0.05) 
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Purpose or Objective: Activation of coagulation and 
fibrinolysis are found among gastric cancer patients. The 
ones with non-metastatic gastric cancer are at risk for 
thrombotic events due to the combined increase in fibrinogen 
plasma levels and thrombin formation. It could be associated 
with a higher risk of local invasion and might be important 
poor predictive and prognostic factor. In our study, we 
sought the associations between blood parameters and 
outcome 
 
Material and Methods: The study examined eighty-nine 
patients with biopsy-proven, operable gastric 
adenocarcinoma, with no evidence of distant metastases. 
Pre-operative fibrinogen, PT, APTT and INR levels were 
measured before surgery . Complete blood count were also 
collected before initiation of therapy . All patients 
underwent surgery as a primary treatment. The survival 
function was computed using Kaplan-Meier method. The 
overall survival (OS), Diseases- free survival (DFS), time to 
distant metastases (DM) and locoregional control (LRC) were 
calculated from the date of surgery. Multivariate analyses 
and characteristic (ROC) have been done. 
 
Results: In Multivariate Cox analysis higher level of WBC was 
associated with worse local control (p=0,0024), and shorter 
overall survival (p=0,0035). Shorter Prothrombin Time was 
correlated with better overall survival (p=0,0280). Higher 
Fibrinogen level has caused better local control (p=0,0280). 
No other correlation between DFS, LRC, DM and OS and other 
blood parameters were observed in multivariate analyses.  
 
Conclusion: The level of White Blood Cells, Fibrinogen and 
Prothrombin Time were found to be useful prognostic factor 
which influenced overall survival and local control. However, 
further prospective investigations are necessary to assess the 
predictive value of those factors. 
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Purpose or Objective: To evaluate the feasibility, efficacy 
and toxicity of robotic SBRT for the treatment of 
unresectable hepatic oligometastases. 
 
Material and Methods: Between 09/2010 and 01/2013, 15 
consecutive patients (12 female, 3 male, median age at 
treatment: 70.5, range: 57-85 years) with up to 3 
synchronous or metachronous hepatic oligometastases were 
referred for Cyberknife treatment (Accuray Incorporated, 
Sunnyvale, CA) at our center. In order to enable tumor 
tracking, gold fiducial markers were inserted around the 
lesion 2 weeks prior to each treatment. The treatment was 
delivered using the Synchrony Respiratory Tracking System to 
continuously track fiducial position and adjust for respiratory 
motion during treatment. Treatment planning was performed 
using the Multiplan TPS (v4.6, Accuray) with Raytracing 
algorithm, and was retrospectively recalculated using a 
Monte Carlo dose calculation algorithm (v5.1). The primary 
endpoint of this study was local control (LC), assessed with 
either contrast enhanced spiral CT or MRI. Secondary 
endpoints were liver and distant progression free-survival 
(liverPFS and DFS), overall survival (OS) and treatment 
toxicity, evaluated using the Common Terminology Criteria 
for Adverse Events v4.0. (Institute NC, NIH publication 2009). 
Statistical analysis was performed using R software (3.1.1, R 
Development Core Team 2010). 
 
Results: A total of 20 metastatic lesions were treated from 
primary colorectal (7), breast (7), unknown primary (3), 
melanoma (2) and stomach (1) cancer. The mean GTV and 
PTV volumes were 23.8cc (Standard deviation (SD):23) and 
74.5cc (SD:45.3) respectively. All treatments were delivered 
3x/week in a median three fractions (range: 3-6) to a median 
dose of 45 Gy (range: 30-45), prescribed to the 80% isodose 
line. This corresponds to an equivalent 2-Gy dose of 93.75Gy, 
